Last reviewed · How we verify
Carboplatin+Paclitaxel
Carboplatin and paclitaxel work together as a chemotherapy combination: carboplatin cross-links DNA to prevent replication, while paclitaxel stabilizes microtubules to disrupt cell division.
Carboplatin and paclitaxel work together as a chemotherapy combination: carboplatin cross-links DNA to prevent replication, while paclitaxel stabilizes microtubules to disrupt cell division. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.
At a glance
| Generic name | Carboplatin+Paclitaxel |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Chemotherapy combination (platinum agent + taxane) |
| Target | DNA (carboplatin); beta-tubulin (paclitaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin is a platinum-based alkylating agent that binds to DNA and forms interstrand crosslinks, preventing DNA replication and transcription in cancer cells. Paclitaxel is a taxane that binds to beta-tubulin and stabilizes microtubules, preventing their depolymerization and causing mitotic arrest. Together, they provide synergistic cytotoxic effects across multiple phases of the cell cycle.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Breast cancer
- Head and neck cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Nausea and vomiting
- Alopecia
- Fatigue
- Hypersensitivity reactions
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1) (NA)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatin+Paclitaxel CI brief — competitive landscape report
- Carboplatin+Paclitaxel updates RSS · CI watch RSS
- AstraZeneca portfolio CI